What is the first hormone produced in cholesterol synthesis?
Which of the following is a precursor for the production of second messengers?
Which of the following oils contains the maximum amount of essential fatty acids?
Which of the following has the highest percentage of polyunsaturated fatty acids?
The only energy-requiring step in fatty acid oxidation is catalyzed by which enzyme?
In a child with cerebrohepatorenal syndrome presenting with hypotonia and hepatomegaly, the probable biochemical defect involves the accumulation of which substance?
Deficiency in the lipoprotein lipase enzyme leads to which type of hyperlipoproteinemia?
Which of the following is a cardioprotective fatty acid?
What is the primary storage form of energy in adipose tissue?
The small intestine secretes various triglyceride-rich lipoproteins, but the liver secretes only which type?
Explanation: **Explanation:** The synthesis of cholesterol is a complex, multi-step process occurring primarily in the liver. The correct answer is **Lanosterol**, which is the **first tetracyclic sterol** (the characteristic four-ring steroid nucleus) formed in the pathway. The pathway follows this high-yield sequence: 1. **Acetyl-CoA** → HMG-CoA 2. **HMG-CoA** is reduced to **Mevalonate** (Rate-limiting step via *HMG-CoA Reductase*) 3. Mevalonate → Isoprenoid units (IPPs) → **Squalene** (a linear 30-carbon hydrocarbon) 4. Squalene undergoes cyclization to form **Lanosterol**. 5. Lanosterol then undergoes a series of approximately 19 steps to finally become **Cholesterol**. **Analysis of Incorrect Options:** * **A. Epinephrine:** This is a catecholamine hormone derived from the amino acid **Tyrosine**, not cholesterol. * **B. Ergosterol:** This is a sterol found in **fungal cell membranes**. While structurally similar to cholesterol, it is not an intermediate in human cholesterol synthesis. * **D. Secretin:** This is a peptide hormone produced by the S-cells of the duodenum; it is not derived from the lipid synthesis pathway. **High-Yield Clinical Pearls for NEET-PG:** * **Rate-Limiting Enzyme:** HMG-CoA Reductase (Target of **Statins**). * **Location:** Synthesis occurs in the **Cytosol** and **Endoplasmic Reticulum**. * **Key Intermediate:** Squalene is the last linear precursor before cyclization. * **Requirement:** Synthesis requires **NADPH** (primarily from the HMP Shunt) and **ATP**.
Explanation: **Explanation:** **1. Why Phosphatidylinositol is Correct:** Phosphatidylinositol (PI) is a minor but vital phospholipid found in the inner leaflet of the plasma membrane. It undergoes phosphorylation to form **Phosphatidylinositol 4,5-bisphosphate (PIP₂)**. Upon stimulation by hormones or neurotransmitters, the enzyme **Phospholipase C (PLC)** cleaves PIP₂ into two potent second messengers: * **Inositol 1,4,5-trisphosphate (IP₃):** Mobilizes calcium (Ca²⁺) from the endoplasmic reticulum. * **Diacylglycerol (DAG):** Activates Protein Kinase C (PKC). This IP₃/DAG pathway is a fundamental signal transduction mechanism for various hormones like Oxytocin, ADH (V1 receptors), and Catecholamines (α1 receptors). **2. Why the Other Options are Incorrect:** * **Phosphatidylserine (B):** Primarily functions in maintaining membrane structural integrity and plays a critical role in **apoptosis**. When it flips from the inner to the outer leaflet, it serves as an "eat-me" signal for macrophages. * **Phosphatidylcholine (C):** Also known as **Lecithin**, it is the most abundant phospholipid in the cell membrane and a major component of lung surfactant (Dipalmitoyl-lecithin). While it can be a source of arachidonic acid, it is not the primary precursor for the IP₃/DAG second messenger system. **3. NEET-PG High-Yield Clinical Pearls:** * **Surfactant:** Deficiency of Dipalmitoyl-phosphatidylcholine leads to Respiratory Distress Syndrome (RDS) in neonates. * **GPI Anchors:** Glycosylphosphatidylinositol (GPI) anchors attach proteins to the cell surface; a deficiency in these anchors on RBCs leads to **Paroxysmal Nocturnal Hemoglobinuria (PNH)**. * **Lipid Signaling:** Phosphatidylinositol 3-kinase (PI3K) is a major target in cancer research due to its role in cell growth signaling.
Explanation: ### Explanation **Core Concept: Essential Fatty Acids (EFAs)** Essential fatty acids are those that the human body cannot synthesize due to the absence of enzymes ($\Delta^{12}$ and $\Delta^{15}$ desaturases) that introduce double bonds beyond the $\Delta^9$ carbon. The two primary EFAs are **Linoleic acid ($\omega$-6)** and **$\alpha$-Linolenic acid ($\omega$-3)**. **Why Sunflower Oil is Correct:** Sunflower oil is exceptionally rich in **Linoleic acid**, which constitutes approximately **60-70%** of its total fatty acid profile. Among the given options, it provides the highest concentration of polyunsaturated fatty acids (PUFAs), making it the richest source of EFAs. **Analysis of Incorrect Options:** * **Coconut Oil:** It is predominantly composed of **Saturated Fatty Acids (90%)**, mainly Lauric acid. It contains negligible amounts of EFAs and is often cited as the least healthy option regarding PUFA content. * **Mustard Oil:** While it contains some linoleic and alpha-linolenic acid, it is characterized by high levels of **Erucic acid** (a monounsaturated fatty acid), which has been linked to myocardial fibrosis in animal studies. * **Groundnut (Peanut) Oil:** This is primarily a source of **Monounsaturated Fatty Acids (MUFAs)**, specifically Oleic acid. While it contains some linoleic acid (~20-30%), it is significantly lower than sunflower oil. **High-Yield Clinical Pearls for NEET-PG:** * **Phrynoderma (Toad Skin):** A clinical manifestation of EFA deficiency characterized by follicular hyperkeratosis on the extensor surfaces of limbs. * **P/S Ratio:** The ratio of Polyunsaturated to Saturated fatty acids. A higher P/S ratio (like in sunflower or safflower oil) is considered "heart-healthy" as it helps lower LDL cholesterol. * **Safflower Oil:** If listed, safflower oil generally contains even higher linoleic acid (~75%) than sunflower oil. * **Eicosanoids:** EFAs serve as precursors for the synthesis of prostaglandins, thromboxanes, and leukotrienes.
Explanation: **Explanation:** The question tests the knowledge of the fatty acid composition of common dietary fats. **Polyunsaturated Fatty Acids (PUFAs)** are fatty acids containing more than one double bond in their backbone (e.g., Linoleic acid and Linolenic acid). **Why Soya bean oil is correct:** Soya bean oil is highly rich in PUFAs, containing approximately **58–62%** (primarily Linoleic acid). Among the given options, it has the highest concentration of these heart-healthy fats, which are known to lower LDL cholesterol levels. **Analysis of Incorrect Options:** * **Margarine:** While often made from vegetable oils, the process of **hydrogenation** used to make it solid converts many unsaturated fats into saturated fats and trans-fats. Thus, its PUFA content is lower than liquid vegetable oils. * **Palm oil:** This is a "tropical oil" and is unique among plant oils for being very high in **saturated fatty acids** (~50%, mainly Palmitic acid). It has a relatively low PUFA content (~10%). * **Groundnut (Peanut) oil:** This oil is primarily rich in **Monounsaturated Fatty Acids (MUFAs)**, specifically Oleic acid (~45-50%). Its PUFA content is significant (~30%) but substantially lower than that of Soya bean oil. **High-Yield Clinical Pearls for NEET-PG:** * **Highest PUFA content:** Safflower oil (>70%) > Sunflower oil > Soya bean oil. * **Highest MUFA content:** Olive oil (highest) > Groundnut oil. * **Highest Saturated fat (Plant source):** Coconut oil (>90%). * **Essential Fatty Acids (EFA):** Linoleic (ω-6) and Linolenic (ω-3) acids are PUFAs that cannot be synthesized by the body and must be obtained from the diet. * **P:S Ratio:** A high Polyunsaturated to Saturated fat ratio is considered anti-atherogenic. Safflower and Soya bean oils have favorable P:S ratios.
Explanation: ### Explanation The correct answer is **Thiokinase** (also known as **Acyl-CoA Synthetase**). **1. Why Thiokinase is Correct:** Fatty acid oxidation (Beta-oxidation) occurs in the mitochondria, but fatty acids must first be "activated" in the cytosol to enter the metabolic pathway. Thiokinase catalyzes the conversion of a free fatty acid into an **Acyl-CoA**. This is the **only energy-requiring step** in the entire process. It consumes **two high-energy phosphate bonds** because ATP is hydrolyzed to AMP and inorganic pyrophosphate (PPi). The subsequent hydrolysis of PPi by pyrophosphatase makes this reaction irreversible and drives the process forward. **2. Why the Other Options are Incorrect:** * **Acyl-CoA Dehydrogenase (Option B):** This is the first enzyme of the beta-oxidation cycle itself. It involves the oxidation of Acyl-CoA to trans-enoyl-CoA, which **generates energy** in the form of FADH₂ rather than consuming it. * **Thiolase (Option C):** This is the final enzyme of the beta-oxidation cycle. It performs a thiolytic cleavage to release Acetyl-CoA. It does not require ATP. * **Beta-hydroxy Acyl-CoA Dehydrogenase (Option D):** This is the third enzyme of the cycle. It oxidizes the hydroxyl group to a keto group, **generating energy** in the form of NADH. **3. NEET-PG High-Yield Pearls:** * **Location:** Activation (Thiokinase) occurs in the **outer mitochondrial membrane/cytosol**, while the actual oxidation occurs in the **mitochondrial matrix**. * **The Carnitine Shuttle:** While Thiokinase activates the fatty acid, the **Carnitine palmitoyltransferase (CPT) system** is the rate-limiting step for transporting long-chain fatty acids into the mitochondria. * **Net ATP Calculation:** When calculating the net ATP yield of palmitic acid (106 ATP), we subtract **2 ATP** specifically because of the Thiokinase step (ATP → AMP).
Explanation: **Explanation:** **1. Why "Very long chain fatty acids" (VLCFAs) is correct:** The clinical presentation described—hypotonia, hepatomegaly, and "cerebrohepatorenal syndrome"—is the classic triad of **Zellweger Syndrome**. This is an autosomal recessive peroxisomal biogenesis disorder caused by mutations in *PEX* genes. Peroxisomes are essential for the **$\beta$-oxidation of Very Long Chain Fatty Acids (VLCFAs)** (fatty acids with $\ge$ 22 carbons). When peroxisomes are absent or dysfunctional, VLCFAs cannot be broken down and instead accumulate in the blood and tissues, particularly the brain and liver, leading to demyelination and organ dysfunction. **2. Why the other options are incorrect:** * **Pyruvate:** Accumulation is typically seen in Pyruvate Dehydrogenase deficiency or B1 deficiency, leading to lactic acidosis, not peroxisomal disorders. * **Short chain fatty acids:** These are metabolized in the mitochondria. Peroxisomes are specifically required for the initial breakdown of very long chains; once shortened, they are transferred to mitochondria. * **Acetyl CoA:** This is a product of fatty acid oxidation, not a substance that accumulates due to a lack of peroxisomes. In fact, impaired $\beta$-oxidation would lead to *decreased* production of Acetyl CoA. **High-Yield NEET-PG Clinical Pearls:** * **Zellweger Syndrome:** Often called "Empty Peroxisome" syndrome. Look for craniofacial dysmorphism (high forehead, wide fontanelles) and stippled epiphyses (chondrodysplasia punctata) on X-ray. * **Refsum Disease:** Another peroxisomal disorder, but due to a defect in **$\alpha$-oxidation**, leading to the accumulation of **Phytanic acid**. * **Adrenoleukodystrophy (ALD):** X-linked defect in the transport of VLCFAs into peroxisomes (ABCD1 mutation), leading to adrenal insufficiency and white matter loss.
Explanation: **Explanation:** **Type I Hyperlipoproteinemia** (Familial Chylomicronemia Syndrome) is primarily caused by a genetic deficiency in **Lipoprotein Lipase (LPL)** or its essential cofactor, **Apo C-II**. LPL is the key enzyme responsible for hydrolyzing triglycerides within chylomicrons and VLDL. When LPL is deficient, chylomicrons cannot be cleared from the blood, leading to severe hypertriglyceridemia and a milky appearance of the plasma. **Analysis of Incorrect Options:** * **Type IIa (Familial Hypercholesterolemia):** Caused by a deficiency in **LDL receptors**, leading to isolated elevation of LDL and cholesterol. * **Type IIb (Combined Hyperlipidemia):** Characterized by decreased LDL receptors and increased ApoB-100, resulting in elevated LDL and VLDL. * **Type III (Dysbetalipoproteinemia):** Caused by a deficiency in **Apo E**, which prevents the hepatic uptake of chylomicron remnants and IDL (Beta-VLDL). **NEET-PG High-Yield Pearls:** * **Clinical Triad of Type I:** Eruptive xanthomas, Hepatosplenomegaly, and Recurrent Pancreatitis (due to massive triglyceride levels). * **Diagnostic Test:** The "Refrigeration Test" shows a creamy layer on top (chylomicrons) with a clear underlying infranatant. * **Apo C-II:** Remember that Apo C-II is the "key" that activates LPL; its deficiency mimics LPL deficiency (also Type I). * **Treatment:** Unlike other types, Type I does not respond well to fibrates or statins; the primary management is a **strict low-fat diet**.
Explanation: **Explanation:** **Correct Answer: C. Oleic acid** **1. Why Oleic acid is correct:** Oleic acid (18:1; ω-9) is a **Monounsaturated Fatty Acid (MUFA)** and is the primary component of olive oil. It is considered cardioprotective because it effectively lowers **LDL-cholesterol** (the "bad" cholesterol) while maintaining or slightly increasing **HDL-cholesterol** (the "good" cholesterol). By improving the lipid profile and reducing oxidative stress on vascular endothelium, it decreases the risk of atherosclerosis and coronary heart disease (CHD). **2. Why other options are incorrect:** * **A & B (Palmitic and Stearic acid):** These are **Saturated Fatty Acids (SFA)**. Palmitic acid (16:0) is highly atherogenic as it significantly raises plasma LDL levels. While Stearic acid (18:0) is considered "neutral" because it is rapidly converted to oleic acid in the body, it is not classified as actively cardioprotective compared to MUFAs. * **D (Omega-3 fatty acids):** While Omega-3s (like EPA and DHA) are indeed cardioprotective, in the context of standard medical examinations, **Oleic acid** is the classic answer when discussing the benefits of the "Mediterranean Diet." *Note: If this were a multiple-select question, Omega-3 would be correct, but Oleic acid is the high-yield MUFA representative for this specific topic.* **3. High-Yield Clinical Pearls for NEET-PG:** * **P:S Ratio:** A high Polyunsaturated to Saturated fatty acid ratio in the diet is associated with lower cardiovascular risk. * **Trans-fatty acids:** These are the most harmful; they raise LDL and lower HDL. * **Mediterranean Diet:** Rich in Oleic acid (Olive oil), it is the gold standard for nutritional cardioprotection. * **Essential Fatty Acids:** Linoleic (ω-6) and Linolenic (ω-3) acids cannot be synthesized by humans due to the lack of desaturases beyond carbon 9.
Explanation: **Explanation:** **Triglycerides (Triacylglycerols)** are the primary storage form of energy in adipose tissue. They consist of three fatty acid chains esterified to a glycerol backbone. They are the ideal storage molecule because they are **highly reduced** (yielding 9 kcal/g compared to 4 kcal/g for carbohydrates) and **anhydrous** (hydrophobic), meaning they do not require water for storage, unlike glycogen. This allows the body to store a vast amount of energy in a compact form. **Analysis of Incorrect Options:** * **Glucose:** This is the primary circulating fuel in the blood, not a storage form. In the body, glucose is stored as **glycogen** (primarily in the liver and muscle), but its storage capacity is limited and heavy due to its high water content. * **Phospholipids:** While these are major lipid components, their primary role is **structural**. They form the lipid bilayer of cell membranes and are not utilized as a significant energy reservoir. **High-Yield Clinical Pearls for NEET-PG:** * **Hormone-Sensitive Lipase (HSL):** This is the rate-limiting enzyme for mobilizing triglycerides from adipose tissue during fasting. It is activated by Glucagon and Epinephrine (via cAMP) and inhibited by Insulin. * **Perilipin:** A protein that coats the lipid droplet in adipocytes, protecting triglycerides from degradation until hormonal signals trigger lipolysis. * **Energy Density:** Adipose tissue provides enough energy to sustain a normal human for 30–40 days, whereas glycogen stores are depleted within 24 hours.
Explanation: ### Explanation The liver and the small intestine are the two primary sites for the synthesis of triglyceride-rich lipoproteins. However, they utilize different apolipoproteins and pathways based on the source of the lipids. **1. Why VLDL is the Correct Answer:** The liver synthesizes **VLDL (Very Low-Density Lipoprotein)** to transport endogenous triglycerides (synthesized in the liver from excess carbohydrates or free fatty acids) to peripheral tissues. The structural hallmark of VLDL is **Apo B-100**. While the liver can produce HDL precursors, VLDL is the specific triglyceride-rich lipoprotein it secretes into the circulation. **2. Analysis of Incorrect Options:** * **A. Chylomicrons:** These are synthesized exclusively by the **enterocytes of the small intestine** to transport exogenous (dietary) lipids. They contain **Apo B-48**, a truncated version of Apo B-100 produced via RNA editing. * **C. LDL:** LDL is not secreted directly by any organ. It is a "metabolic end-product" formed in the plasma from VLDL via the action of Lipoprotein Lipase (LPL) and Cholesterol Ester Transfer Protein (CETP). * **D. HDL:** While the liver and intestine both secrete nascent HDL (Apo A-1), HDL is a **cholesterol-rich** lipoprotein, not a triglyceride-rich one. Its primary role is reverse cholesterol transport. **3. NEET-PG High-Yield Facts:** * **Apo B-48 vs. Apo B-100:** Both are products of the same gene. In the intestine, the enzyme **cytidine deaminase** creates a stop codon, resulting in the shorter Apo B-48 (48% of the protein). * **Abetalipoproteinemia:** A deficiency of Microsomal Triglyceride Transfer Protein (MTP) leads to an inability to load lipids onto Apo B, resulting in the absence of both Chylomicrons and VLDL. * **Rate-limiting step:** The assembly of VLDL in the liver requires MTP and Apo B-100.
Lipid Classification and Chemistry
Practice Questions
Fatty Acid Oxidation
Practice Questions
Ketone Body Metabolism
Practice Questions
Fatty Acid Synthesis
Practice Questions
Metabolism of Triacylglycerols
Practice Questions
Phospholipid Metabolism
Practice Questions
Cholesterol Metabolism and Biosynthesis
Practice Questions
Bile Acids and Bile Salts
Practice Questions
Lipoprotein Metabolism and Transport
Practice Questions
Dyslipidemias and Atherosclerosis
Practice Questions
Prostaglandins and Eicosanoids
Practice Questions
Fatty Liver and Lipotropic Factors
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free